Jenscare Unveils Impressive 2025 Interim Results
Jenscare Scientific Co., Ltd. (HKEX: 9877) has recently shared its interim results for the first half of 2025, reflecting a period of intense growth and significant milestones in its innovative medical device offerings. The company’s developments represent pivotal breakthroughs in the field of transcatheter therapies, particularly in treating valve diseases.
Product Pipeline Progress
The 2025 first half showcased remarkable advancements within Jenscare's product pipeline. The company focuses on interventional treatments for tricuspid, aortic, and mitral valve diseases, laying strong foundations for a diverse and future-ready product portfolio. Jenscare's global outreach has expanded, enhancing the efficacy and clinical application scale of its products, which is pivotal for sustainable high-speed growth.
LuX-Valve Plus: Clinical Achievements
One of the company’s highlights is the LuX-Valve Plus TTVR system, which achieved critical milestones in several regions. The multicenter registration clinical trial in China is currently in a follow-up phase, exhibiting excellent outcomes and solidifying its potential in the market. Jenscare’s progress towards acquiring official NMPA registration is on track, with applications submitted and accepted for review.
Clinical Trials in Europe and the U.S.
In Europe, the company completed a significant 6-month follow-up for its global multicenter clinical trial, the TRINITY Study, which is essential for CE Marking. Results released at major conferences revealed promising clinical outcomes across various patient demographics, highlighting the growing applicability of the LuX-Valve Plus system.
Ken-Valve TAVR System: Rapid Market Adaptation
Another standout in Jenscare's portfolio is the Ken-Valve TAVR system. Following its approval by NMPA in 2025, the Ken-Valve is witnessing swift market penetration. Positive feedback from healthcare providers emphasizes its innovative design and optimal performance, addressing crucial clinical needs for severe aortic regurgitation and complex anatomies.
Efforts in Commercialization
The commercialization strategy for Ken-Valve is well underway, with a focus on expanding hospital access and conducting numerous implantations nationwide. Jenscare is prioritizing agile marketing strategies, targeting clinical education, and ensuring the highest procedural standards during implementation.
Innovative Developments: JensClip TMVr System
Additionally, Jenscare announced that the JensClip TMVr system has entered the registration phase for NMPA, with clinical follow-up results presented at significant European meetings indicating high efficacy and safety levels. The ongoing globalization efforts include successful pre-commercial implantations overseas, preparing the company for wider market entry.
Strategic Global Sales Network
In the quest for worldwide growth, Jenscare has established a global sales network, particularly in China, creating a robust distributor framework with flexible pricing strategies. The concerted marketing efforts are aimed at maximizing product awareness and expanding market share swiftly.
Comprehensive Training and Support
The company has implemented extensive training programs to equip its teams and partners with the necessary skills for product deployment. These initiatives are part of Jenscare's broader strategy to facilitate rapid adoption and ensure top-quality procedures during product launch.
Future Growth and Expectations
Looking ahead, Jenscare is committed to evolving its product lineup and enhancing its clinical offerings. The goal is clear: to establish itself as a leading entity in the medical device landscape with a focus on addressing urgent needs in structural heart treatment. With effective operational enhancements, Jenscare is set to capture growth opportunities, ensuring long-term success through innovative solutions.
Financial Highlights: Quality Growth
The financial performance for 2025H1 reveals total revenue reaching RMB 26 million (approximately US$ 3.6 million), marking a promising beginning for its commercialization efforts. The gross profit reached RMB 12 million (around US$ 1.7 million), contributing to a gross profit margin nearing 90%. Additionally, while the adjusted non-IFRS loss for the period was RMB 92 million (about US$ 12.9 million), it has shown a decrease compared to preceding periods, indicating improved operational efficiency.
Frequently Asked Questions
What is Jenscare's focus area?
Jenscare focuses on innovative medical devices for treating heart valve diseases, aiming for advanced transcatheter therapies.
What are the results of the Ken-Valve TAVR system?
The Ken-Valve TAVR system is rapidly gaining market access following positive feedback regarding its design and clinical effectiveness.
What milestones has the LuX-Valve Plus achieved?
The LuX-Valve Plus has reached significant clinical trial milestones and is currently progressing toward NMPA certification.
How is Jenscare expanding its global presence?
Jenscare is establishing comprehensive distributor networks and conducting market research to facilitate its global product launches.
What are Jenscare's future growth strategies?
Jenscare aims to expand its innovative product portfolio and enhance clinical offerings to address key market needs in structural heart disease.
